Posted by Michael Wonder on 28 Mar 2018
Final NICE green light for Ipsen’s Cometriq
28 March 2018 - Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid cancer (MTC) in England and Wales.
The National Institute for Health and Care Excellence has issued guidelines recommending the drug as an option for treating progressive MTC in adults with unresectable, locally advanced or metastatic disease.
This is a rare cancer, accounting for 3-12% of all thyroid cancers, and can spread to the lungs or bone. Approximately 25 percent of MTCs are the result of an inherited faulty gene that runs in the family.
